SCOTTSDALE, Ariz. — Oct. 4, 2023 — HonorHealth Research Institute is consulting the people of Scottsdale and Phoenix about whether to lead a local trauma research study to investigate a blood clotting agent as a treatment for trauma patients who are bleeding to death.Continue reading
Category Archives: AZBio News
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
The Spin-off of Sandoz enables Novartis to complete its transformation to become a leading, focused medicines company. With capital allocation and management attention fully focused on innovative medicines, Novartis is well-positioned for sustained top- and bottom-line growth.Continue reading
Ceria Therapeutics, Inc. Awarded a $3,800,000 DoD Contract to Advance Development of a Novel Treatment for Acute Lung Injuries.
The award will go towards the development of CTX-002 in preparation for clinical studies.
Student-faculty team of inventors spin out tools to remove stuck orthpedic screws
Startup Ancerix to commercialize much needed tool kit for surgeons
Continue reading
Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
Data shared via a poster presentation at the recent American Foregut Society (AFS) Annual MeetingContinue reading
ACLA Opposes Unilateral FDA Action to Regulate Laboratory Developed Tests Under Medical Device Authority
Washington, D.C. – The American Clinical Laboratory Association (ACLA) today issued the following statement after the U.S. Food and Drug Administration (FDA) released a proposed rule that would seek to regulate Laboratory Developed Tests (LDTs) as medical devices under the Federal Food, Drug, and Cosmetic Act. ACLA does not believe that FDA’s actions are in the best interest of patients or our nation’s health care system. Because the proposed rule exceeds FDA’s existing authority, ACLA plans to submit comments urging FDA to withdraw the proposed rule and resume work with Congress, the laboratory community, patient groups, and other stakeholders toward a legislative solution that provides a framework that is appropriate for the unique attributes of LDTs.Continue reading
FDA Proposes Rule Aimed at Helping to Ensure Safety and Effectiveness of Laboratory Developed Tests
For Immediate Release:
September 29, 2023
Today, the U.S. Food and Drug Administration announced a proposed rule regarding laboratory developed tests, or LDTs, which play an important role in healthcare. The rule is aimed at helping to ensure the safety and effectiveness of these tests, which are used in a growing number of health care decisions and for which concerns have been raised for many years.Continue reading
Design of a new NAU medical school part of ABOR’s comprehensive effort to improve health outcomes across Arizona
Arizona will see its first medical school in Flagstaff as part of the Arizona Board of Regents’ call to its public universities to close the health care workforce gap in the state.Continue reading
Cancer Drug Developer Dr. Steve Potts’ Congressional Testimony on the IRA
AZBio Board Member Dr. Steve Potts discusses the negative impacts provisions of the Inflation Reduction Act (IRA) are having on the health innovation pipeline with Duane Schulthess, Managing Director of Vital Transformation, on the Vital Health Podcast.Continue reading